Articles By Cyndi Root

31. Merrimack Pharmaceuticals' MM-141 Named FDA Orphan Drug For Pancreatic Cancer 11/10/2014

    Merrimack Pharmaceuticals announced in a press release that the Food and Drug Administration (FDA) granted Orphan Drug designation to MM-141.

32. Astellas', Basilea's Isavuconazole Granted FDA Orphan Drug Status For Invasive Candidiasis 11/9/2014

    Astellas’ and Basilea’s Isavuconazole continues its upwards trajectory as the Food and Drug Administration (FDA) has granted the agent Orphan Drug status for invasive candidiasis.

33. Abide Therapeutics, University Of Oxford Collaborate On Serine Hydrolases 11/9/2014

    Abide Therapeutics has partnered with the University of Oxford to research serine hydrolases, an under explored enzyme class.

34. Proteostasis, Astellas Partner On Unfolded Protein Response Therapeutics 11/7/2014

    Proteostasis Therapeutics and Astellas Pharma have begun a partnership to develop therapeutics modulating the Unfolded Protein Response (UPR).

35. FDA Clears ISCO's Parthenogenetic Stem Cells For Investigational Clinical Use 11/7/2014

    International Stem Cell Corporation is now approved to manufacture human parthenogenetic stem cells.

36. SCYNEXIS Licenses SCY-635 To Waterstone For Viral Diseases 11/6/2014

    SCYNEXIS has licensed SCY-635 to Waterstone Pharmaceutical for the treatment of human viral diseases. SCYNEXIS announced the move in a press release, stating that it allows the company to focus on other compounds in development.

37. Bristol-Myers Squibb Acquires Galecto Biotech, Galectin-3 Inhibitor For IPF 11/5/2014

    Bristol-Myers Squibb (BMS) has acquired an option to buy Galecto Biotech AB and the worldwide rights to TD139.

38. New Life In Cancer Drugs Targretin, Tasigna For Alzheimer's, Study Finds 11/5/2014

    New research has found that cancer drugs Targretin and Tasigna may be effective in treating Alzheimer’s Disease.

39. FDA Committee Recommends Daiichi Sankyo's Savaysa For Stroke 11/4/2014

    A Food and Drug Administration (FDA) committee voted 9 to 1 to recommend Daiichi Sankyo’s Savaysa (edoxaban) for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

40. FDA Awards Orphan Status To RetroSense's RST-001 For Retinitis Pigmentosa 11/4/2014

    RetroSense Therapeutics announced in a press release that the Food and Drug Administration (FDA) has granted Orphan Drug status to RST-001.